Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04301011
Title Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Turnstone Biologics, Corp.

triple-receptor negative breast cancer

colorectal cancer

Advanced Solid Tumor



Pembrolizumab + TBio-6517

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.